Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:40 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma
NCT02811679 · Massachusetts General Hospital · PHASE2 · terminated · last registry update 2025-05-23 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study closed early due to slow accrual” | – | Registry record, Massachusetts General Hospital |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD3E within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-05-13Results posted on the registry: University of Washington, Mosunetuzumab + Obinutuzumab (NCT05169658)
- 2026-05-13Results posted on the registry: Amgen, Blinatumomab (NCT06649006)
- 2026-05-06Phase 3 first posted: Merck Sharp & Dohme LLC, MK-1045 + Blinatumomab (NCT07570173)
- 2026-05-06Also stopped (terminated): Pfizer, maplirpacept (PF-07901801) + Glofitamab (NCT05896163)
- 2026-04-28Also stopped (withdrawn): National Cancer Institute (NCI), Tarlatamab + Sacituzumab Govitecan (NCT07328490)
- 2026-04-24Also stopped (terminated): Pfizer, Elranatamab + Nirogacestat + Elranatamab + lenalidomide + dexamethasone (NCT05090566)
- 2026-04-15Results posted on the registry: Amgen, Tarlatamab (NCT06502977)
- 2026-04-08Phase 3 first posted: Janssen Research & Development, LLC, JNJ-79635322 + Teclistamab (NCT07518186)
- 2026-04-07Also stopped (withdrawn): Memorial Sloan Kettering Cancer Center, Epcoritamab + Lenalidomide (NCT07030699)
- 2026-03-17Phase 3 first posted: Charite University, Berlin, Germany, Inotuzumab ozogamicin (INO) + Blinatumomab (NCT07476729)
- 2026-03-06Results posted on the registry: Hoffmann-La Roche, Mosunetuzumab + Polatuzumab vedotin (NCT05171647)
- 2026-03-04Results posted on the registry: St. Jude Children's Research Hospital, Cyclophosphamide + Fludarabine (NCT03849651)
- 2026-02-23Results posted on the registry: Pfizer, Elranatamab + Nirogacestat + Elranatamab + lenalidomide + dexamethasone (NCT05090566)
- 2025-12-22Phase 3 first posted: Bambino Gesù Hospital and Research Institute, Ruxolitinib + Blinatumomab (NCT07297914)
- 2025-12-02Phase 3 first posted: Janssen Research & Development, LLC, JNJ-79635322 + Teclistamab (NCT07258511)
- 2025-11-10Phase 3 first posted: Genmab, Epcoritamab + Investigator's Choice Chemotherapy (NCT07226752)
- 2025-10-31Phase 3 first posted: Amgen, Blinatumomab + Blinatumomab (NCT07223190)
- 2025-09-22Results posted on the registry: St. Jude Children's Research Hospital, Venetoclax + Navitoclax (NCT05192889)
- 2025-08-22Phase 3 first posted: Qilu Pharmaceutical Co., Ltd., QLS32015 + Pomalidomide (NCT07138209)
- 2025-07-28Phase 3 first posted: Sanofi, Teplizumab (NCT07088068)
- 2025-06-05Phase 3 first posted: Amgen, Tarlatamab + Durvalumab (NCT07005128)
- 2025-04-09Phase 3 first posted: Intergroupe Francophone du Myelome, Elranatamab + Lenalidomide (Revlimid®) (NCT06918002)
- 2025-01-08Phase 3 first posted: Institute of Hematology & Blood Diseases Hospital, China, Blinatumomab (Group A) + Venetoclax (nonRand Group) (NCT06764238)
- 2024-10-16Results posted on the registry: National Cancer Institute (NCI), Blinatumomab + Ipilimumab (NCT02879695)
- 2024-09-24Results posted on the registry: National Cancer Institute (NCI), Blinatumomab + Cyclophosphamide (NCT02003222)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision